Vertex Pharmaceuticals Incorporated
VRTX
$472.64
-$5.25-1.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.19B | 1.08B | 1.03B | 646.30M | 913.00M |
| Total Depreciation and Amortization | 24.50M | 54.00M | 51.70M | 48.40M | 21.30M |
| Total Amortization of Deferred Charges | 31.20M | -- | -- | -- | 25.20M |
| Total Other Non-Cash Items | 199.00M | -45.10M | 120.90M | 392.70M | 185.30M |
| Change in Net Operating Assets | -947.80M | 149.60M | -132.40M | -268.50M | -560.20M |
| Cash from Operations | 498.00M | 1.24B | 1.07B | 818.90M | 584.60M |
| Capital Expenditure | -149.40M | -101.80M | -145.70M | -40.70M | -92.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -138.70M | -15.20M | -338.80M | -15.10M | -729.30M |
| Cash from Investing | -288.10M | -117.00M | -484.50M | -55.80M | -821.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.40M | -1.40M | -1.30M | -1.30M | -1.30M |
| Issuance of Common Stock | 54.00M | 7.90M | 49.10M | 16.70M | 34.30M |
| Repurchase of Common Stock | -130.90M | -1.16B | -397.70M | -696.60M | -425.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.10M | 1.10M | 700.00K | 800.00K | 900.00K |
| Cash from Financing | -77.20M | -1.15B | -349.20M | -680.40M | -391.30M |
| Foreign Exchange rate Adjustments | 7.30M | -4.10M | 57.20M | 30.50M | -47.30M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.00M | -34.20M | 296.60M | 113.20M | -675.90M |